Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Halozyme Therapeutics, Inc. (HALO : NSDQ)
 
 • Company Description   
Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company also licenses its novel drug delivery technology, ENHANZE. Several companies including Roche, Takeda, J&J, AbbVie, Lilly, Bristol-Myers and others are using this technology for developing subcutaneous formulation of their currently marketed drugs. It also recognizes revenues from sale of drug products to its collaboration partners for development of drugs using its ENHANZE platform. The company also has one approved product in its portfolio, Hylenex recombinant as an adjuvant to facilitate subcutaneous fluid administration. Although Halozyme has one marketed product, it derives the majority of its revenues from royalties on sales of partnered drugs.

Number of Employees: 145

 
 • Price / Volume Information   
Yesterday's Closing Price: $44.32 Daily Weekly Monthly
20 Day Moving Average: 1,121,401 shares
Shares Outstanding: 137.95 (millions)
Market Capitalization: $6,113.94 (millions)
Beta: 1.24
52 Week High: $46.62
52 Week Low: $31.36
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 1.72% 14.56%
12 Week 25.62% 38.10%
Year To Date 10.22% 33.22%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
11388 SORRENTO VALLEY ROAD
-
SAN DIEGO,CA 92121
USA
ph: 858-794-8889
fax: 858-704-8311
ir@halozyme.com http://www.halozyme.com
 
 • General Corporate Information   
Officers
Helen I. Torley - ChiefExecutiveOfficer and President
Connie L. Matsui - Chair of the Board of Directors
Nicole LaBrosse - Senior VicePresident andChiefFinancialOfficer
Jean-Pierre Bizzari - Director
Bernadette Connaughton - Director

Peer Information
Halozyme Therapeutics, Inc. (CORR.)
Halozyme Therapeutics, Inc. (RSPI)
Halozyme Therapeutics, Inc. (CGXP)
Halozyme Therapeutics, Inc. (BGEN)
Halozyme Therapeutics, Inc. (GTBP)
Halozyme Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 40637H109
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 137.95
Most Recent Split Date: (:1)
Beta: 1.24
Market Capitalization: $6,113.94 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.47 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $2.08 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 21.31
Trailing 12 Months: 22.50
PEG Ratio: -
Price Ratios
Price/Book: 23.49
Price/Cash Flow: 22.10
Price / Sales: 12.97
EPS Growth
vs. Year Ago Period: 26.47%
vs. Previous Quarter: 10.26%
Sales Growth
vs. Year Ago Period: 31.74%
vs. Previous Quarter: 14.98%
ROE
03/31/22 - 132.71
12/31/21 - 164.68
09/30/21 - 187.85
ROA
03/31/22 - 25.45
12/31/21 - 25.61
09/30/21 - 31.00
Current Ratio
03/31/22 - 8.85
12/31/21 - 7.91
09/30/21 - 8.99
Quick Ratio
03/31/22 - 8.42
12/31/21 - 7.45
09/30/21 - 8.50
Operating Margin
03/31/22 - 60.41
12/31/21 - 61.85
09/30/21 - 62.89
Net Margin
03/31/22 - 92.23
12/31/21 - 90.84
09/30/21 - 88.36
Pre-Tax Margin
03/31/22 - 62.52
12/31/21 - 56.06
09/30/21 - 57.66
Book Value
03/31/22 - 1.89
12/31/21 - 1.40
09/30/21 - 2.00
Inventory Turnover
03/31/22 - 1.46
12/31/21 - 1.44
09/30/21 - 1.47
Debt-to-Equity
03/31/22 - 3.03
12/31/21 - 4.00
09/30/21 - 2.79
Debt-to-Capital
03/31/22 - 75.18
12/31/21 - 79.99
09/30/21 - 73.63
 

Powered by Zacks Investment Research ©